{
  "id": "5c73acf17c78d69471000089",
  "type": "yesno",
  "question": "Is eculizumab used for treatment of myasthenia gravis?",
  "ideal_answer": "Yes, eculizumab is used for treatment of myasthenia gravis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28010051",
    "http://www.ncbi.nlm.nih.gov/pubmed/29337452",
    "http://www.ncbi.nlm.nih.gov/pubmed/23512355",
    "http://www.ncbi.nlm.nih.gov/pubmed/29266249",
    "http://www.ncbi.nlm.nih.gov/pubmed/23945282",
    "http://www.ncbi.nlm.nih.gov/pubmed/29435915",
    "http://www.ncbi.nlm.nih.gov/pubmed/29655452",
    "http://www.ncbi.nlm.nih.gov/pubmed/29066163"
  ],
  "snippets": [
    {
      "text": "Eculizumab treatment improved symptoms compared with placebo in a phase II study in patients with refractory gMG. D",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29266249",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Eculizumab (Soliris) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29337452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The humanized monoclonal antibody eculizumab (Soliris\u00ae) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with symptoms that are difficult to control with high-dose IVIg therapy or PLEX in Japan. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29435915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although several questions remain, such as duration of treatment, cost effectiveness and long-term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gMG.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29435915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the US Food and Drug Administration for myasthenia gravis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29655452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION\nA phase 2 study of eculizumab for treating myasthenia gravis (MG) used the quantitative myasthenia gravis score (QMG) and myasthenia gravis activities of daily living profile (MG-ADL) to evaluate baseline disease severity and treatment response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010051",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Rituximab seems to be particularly effective in MuSK myasthenia gravis, and eculizumab arises as an option in refractory AChR myasthenia gravis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results from a phase 2 study suggested that eculizumab, a terminal complement inhibitor, produced clinically meaningful improvements in patients with anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29066163",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29066163",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The humanized monoclonal antibody eculizumab (Soliris\u00ae) is a complement inhibitor indicated for use in anti-acetylcholine receptor (AChR) antibody-positive adults with generalized myasthenia gravis (gMG) in the USA, refractory gMG in the EU, or gMG with symptoms that are difficult to control with high-dose IVIg therapy or PLEX in Japan.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29435915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Eculizumab (Soliris) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29337452",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Eculizumab: A Review in Generalized Myasthenia Gravis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29435915",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23512355",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Eculizumab: A Review in Generalized Myasthenia Gravis.) ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29435915",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "<b>INTRODUCTION</b>: A phase 2 study of eculizumab for treating myasthenia gravis (MG) used the quantitative myasthenia gravis score (QMG) and myasthenia gravis activities of daily living profile (MG-ADL) to evaluate baseline disease severity and treatment response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Correlations were then analyzed between these assessments.<br><b>METHODS</b>: Patients were given eculizumab or placebo during the first 16-week treatment period of the crossover study, with treatment assignments reversed for the second treatment period following a 5-week washout.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase 2 study of eculizumab for treating myasthenia gravis (MG) used the quantitative myasthenia gravis score (QMG) and myasthenia gravis activities of daily living profile (MG-ADL) to evaluate baseline disease severity and treatment response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28010051",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the US Food and Drug Administration for myasthenia gravis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29655452",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}